Paris, December 2nd ,2021
This funding is composed of a €3 million R&D innovation loan and a recoverable advance of €1.3 million.
Lysogene relies on a gene therapy technology platform targeting a number of central nervous system (CNS) diseases. The funding obtained is intended for the clinical study of the drug candidate LYS-GM101 in the treatment of GM1 gangliosidosis and to prepare preclinical studies of LYS-FXS01 in fragile X syndrome.
De Gaulle Fleurance & Associés (Philippe Feitussi, Partner, Anthony Sarciaux Lawyer – Senior counsel and Géraldine Salem, Lawyer – Senior manager) advised Lysogene in this transaction. “We are particularly pleased to have contributed to the success of this finding”, explains Philippe Feitussi. “This transaction allows Lysogene to accelerate its development in the field of healthcare innovation.
This transaction is the second funding in connection with which De Gaulle Fleurance & Associés is advising Lysogene. In February 2021, the company obtained €5 million from BRED in the form of a state-guaranteed loan (PGE).
Press Contact : Communication, +33 (0)6 82 43 69 62 (Constance Baudry) or +33 (0)1 56 64 00 00 communication@dgfla.com
Metaverse and medical devices: what are the legal issues?
“In 2021, Mark Zuckerberg’s ambition was to bring internet users into the metav...
Unified Patent Court and Unitary Patent: major changes for Patent litigation and licensing in Europe
Unified Patent Court and Unitary Patent: major changes for Patent litigation and lice...
